Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$126.62

-10.64 (-7.75%)

06:46
11/06/18
11/06
06:46
11/06/18
06:46

Sage Therapeutics reports Q3 EPS ($2.63), consensus ($2.42)

Cash, cash equivalents, and marketable securities as of September 30 were $1.0B, compared with $518.8M at December 31, 2017. The increase was primarily due to net proceeds of $631.2M from Sage's follow-on public offering completed in February, and an upfront milestone payment from Shionogi & Co. related to the strategic collaboration that was entered in June.

  • 06

    Nov

  • 06

    Nov

  • 27

    Nov

  • 19

    Dec

SAGE Sage Therapeutics
$126.62

-10.64 (-7.75%)

10/17/18
STFL
10/17/18
NO CHANGE
Target $239
STFL
Buy
Stifel confident in approval of Sage Therapeutics' brexanolone ahead of AdComm
Ahead of an FDA advisory committee meeting on Nov 2 to review brexanolone, Stifel analyst Paul Matteis said he is confident in FDA approval and expects the debate on the drug to be centered on labeling, REMS and necessary monitoring requirements. While noting that brexanolone comprises a minority of his Sage valuation, Matteis said the most important thing for the stock is that the panel is both positive and doesn't raise any sort of issue that would read negatively onto SAGE-217, which comprises the majority of his Sage valuation. He maintains a Buy rating and $239 price target on Sage Therapeutics shares.
10/31/18
BMOC
10/31/18
NO CHANGE
Target $203
BMOC
Outperform
BMO sees approval for Sage after Zulresso briefing docs
The FDA this morning released briefing documents for Friday's panel meeting to discuss Sage Therapeutics' Zulresso to treat postpartum depression. It appears the FDA is satisfied with the drug's efficacy and overall tolerability and recognizes a significant unmet need for postpartum depression, BMO Capital analyst Gary Nachman tells investors in a research note. He believes Zulresso will likely be approved on the December 19 FDA action date. Nachman adds, however, that there are some questions on the recommended dosing, since initially the lower dose appears more effective but the doses start to separate during titration when going out beyond 24 hours. He has an Outperform rating on Sage Therapeutics with a $203 price target. The stock in early trading is up 1% to $122.47.
10/31/18
10/31/18
NO CHANGE
Target $206

Overweight
Sage briefing docs 'clearly supportive of approval,' says Piper Jaffray
In a midday research note partially titled "Nothing Too Spooky in Brex Briefing Docs," Piper Jaffray analyst Danielle Brill says this morning's FDA's briefing documents for Sage Therapeutics' brexanolone were overall supportive of approval for postpartum depression. The agency appears comfortable with brexanolone's efficacy, and focused on recommended dosing as a key topic of discussion, Brill writes in a note to investors. The major safety concern, loss of consciousness during infusion which occurred in 4% of women treated, does not appear to be barring of approval, says the analyst. However, Brill adds that while she views the tone of the docs as "clearly supportive of approval," prohibiting administration "at-home" has "obvious negative implications for commercial potential." She has an Overweight rating on Sage Therapeutics with a $206 price target. The stock in midday trading is up 6%, or $7.77, to $129.00.
11/01/18
ADAM
11/01/18
NO CHANGE
Target $220
ADAM
Buy
Sage Therapeutics FDA briefing documents read 'ok,' says Canaccord
Canaccord analyst Sumant Kulkarni noted the FDA posted its briefing documents related to Sage Therapeutics' brexanolone ahead of the advisory committee meeting on the product scheduled for November 2. The analyst said they appear "ok" and said the drug could be the first approved for the treatment of post-partum depression. The analyst said with the stock down roughly 10% since the FDA confirmed the date of the AdCom meeting, he is telling investors to buy the shares. Kulkarni reiterated his Buy rating and $220 price target on Sage Therapeutics shares.

TODAY'S FREE FLY STORIES

IRWD

Ironwood

$11.96

0.32 (2.75%)

06:01
11/19/18
11/19
06:01
11/19/18
06:01
Recommendations
Ironwood analyst commentary  »

Ironwood price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:00
11/19/18
11/19
06:00
11/19/18
06:00
General news
FX Action: USD-JPY has retained a heavy tone »

FX Action: USD-JPY has…

YETI

Yeti

$16.99

0.1 (0.59%)

05:59
11/19/18
11/19
05:59
11/19/18
05:59
Initiation
Yeti initiated  »

Yeti initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

RHHBY

Roche

$0.00

(0.00%)

05:57
11/19/18
11/19
05:57
11/19/18
05:57
Downgrade
Roche rating change  »

Roche downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 24

    Dec

NVS

Novartis

$87.74

0.52 (0.60%)

05:56
11/19/18
11/19
05:56
11/19/18
05:56
Upgrade
Novartis rating change  »

Novartis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

TI

Telecom Italia

$6.02

0.12 (2.03%)

05:53
11/19/18
11/19
05:53
11/19/18
05:53
Hot Stocks
Telecom Italia appoints Luigi Gubitosi as CEO »

On Sunday, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STNE

StoneCo

$25.31

0.69 (2.80%)

05:51
11/19/18
11/19
05:51
11/19/18
05:51
Initiation
StoneCo initiated  »

StoneCo initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

05:51
11/19/18
11/19
05:51
11/19/18
05:51
Downgrade
AstraZeneca rating change  »

AstraZeneca downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

JPDYY

Japan Display

$0.00

(0.00%)

05:49
11/19/18
11/19
05:49
11/19/18
05:49
Downgrade
Japan Display rating change  »

Japan Display downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTRX

Retrophin

$25.17

0.44 (1.78%)

05:46
11/19/18
11/19
05:46
11/19/18
05:46
Initiation
Retrophin initiated  »

Retrophin initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

YETI

Yeti

$16.99

0.1 (0.59%)

05:43
11/19/18
11/19
05:43
11/19/18
05:43
Initiation
Yeti initiated  »

Yeti initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

EOLS

Evolus

$14.75

0.06 (0.41%)

05:40
11/19/18
11/19
05:40
11/19/18
05:40
Hot Stocks
Evolus announces conditional acceptance from FDA for Jeuveau brand name »

Evolus announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

MNK

Mallinckrodt

$30.85

-0.58 (-1.85%)

05:39
11/19/18
11/19
05:39
11/19/18
05:39
Upgrade
Mallinckrodt rating change  »

Mallinckrodt upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

CPAC

Cementos Pacasmayo

$9.98

(0.00%)

05:38
11/19/18
11/19
05:38
11/19/18
05:38
Upgrade
Cementos Pacasmayo rating change  »

Cementos Pacasmayo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VKTX

Viking Therapeutics

$11.65

0.27 (2.37%)

05:38
11/19/18
11/19
05:38
11/19/18
05:38
Upgrade
Viking Therapeutics rating change  »

Viking Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$23.04

-1.18 (-4.87%)

05:37
11/19/18
11/19
05:37
11/19/18
05:37
Earnings
Breaking Earnings news story on JD.com »

JD.com sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MDGL

Madrigal Pharmaceuticals

$129.47

-3.36 (-2.53%)

05:36
11/19/18
11/19
05:36
11/19/18
05:36
Downgrade
Madrigal Pharmaceuticals rating change  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

JD

JD.com

$23.04

-1.18 (-4.87%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Earnings
JD.com reports Q3 EPS 15c, consensus 10c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AMH

American Homes 4 Rent

$19.83

-0.04 (-0.20%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Downgrade
American Homes 4 Rent rating change  »

American Homes 4 Rent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BB

BlackBerry

$8.97

0.12 (1.36%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Upgrade
BlackBerry rating change  »

BlackBerry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMAX

RE/MAX Holdings

$30.26

-0.23 (-0.75%)

05:34
11/19/18
11/19
05:34
11/19/18
05:34
Upgrade
RE/MAX Holdings rating change  »

RE/MAX Holdings upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

RNG

RingCentral

$76.41

-0.54 (-0.70%)

05:34
11/19/18
11/19
05:34
11/19/18
05:34
Upgrade
RingCentral rating change  »

RingCentral upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

05:33
11/19/18
11/19
05:33
11/19/18
05:33
Upgrade
TD Ameritrade rating change  »

TD Ameritrade upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$46.97

-0.35 (-0.74%)

05:33
11/19/18
11/19
05:33
11/19/18
05:33
Downgrade
Charles Schwab rating change  »

Charles Schwab downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

05:32
11/19/18
11/19
05:32
11/19/18
05:32
Hot Stocks
Nissan finds 'significant acts of misconduct' by Representative Director »

Nissan said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.